Compare Abeona Therapeutics Inc (ABEO) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Home Depot Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Home Depot Inc trades at $354.5 (market cap $349.77B). The key difference: Home Depot Inc is far larger — about 824.3× Abeona Therapeutics Inc's market cap, and Home Depot Inc pays a 2.66% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HD | |
|---|---|---|
Market Cap | $424.33M | $349.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $423.42 |
52-Week Low | $4.17 | $297.51 |
Enterprise Value | $279.23M | $411.32B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in 2025 revenue with solid profitability metrics including 8.41% net income margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations set at $4.73 EPS. The stock faces headwinds from weakening big-ticket demand and rising mortgage rates, but maintains strong analyst support with 59% buy ratings.
Home Depot presents a compelling long-term investment case with stable fundamentals and professional segment growth potential, though near-term challenges include housing market sensitivity and margin pressure. The consensus price target of $368.75 suggests 5.1% upside potential from current levels, supported by strong cash flow generation and dividend payments. Key risks include consumer spending volatility and competitive pressures in the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
